GlassScriptPhysician profile
Gary M Panik
NPI 1073509998
$4,990.04
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,875 · 2020: $1,431 · 2021: $1,601 · 2022: $83.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $987.44 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $724.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $654.97 | 2019-2021 | |
| Lilly USA, LLC | $437.69 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $392.02 | 2019-2021 | |
| Pfizer INC. | $346.73 | 2019-2021 | |
| Glaxosmithkline, LLC. | $323.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $245.80 | 2019-2021 | |
| Esperion Therapeutics, INC. | $139.14 | 2020-2021 | |
| Allergan, INC. | $118.40 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $116.96 | 2021 | |
| Eisai INC. | $79.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $75.27 | 2019-2021 | |
| Amgen INC. | $59.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $45.61 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $28.22 | 2019-2020 | |
| Phadia US INC. | $25.92 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.11 | 2019 | |
| Abbott Laboratories | $24.73 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.69 | 2022 | |
| Abbvie INC. | $21.19 | 2021 | |
| Mannkind Corporation | $20.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.80 | 2019 | |
| Sanofi Pasteur INC. | $15.93 | 2020 | |
| Amarin Pharma, INC. | $14.70 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Panik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.